A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX208 （BRAF V600E Inhibitor） Combined With Serplulimab（HLX10, Anti-PD-1 Antibody） in Advanced NSCLC Patients With BRAF V600E Mutation.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05641493
• Other study ID #: HLX208-NSCLC203
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 28, 2023
• Est. completion date: February 27, 2026

Study information

• Verified date: April 2023
• Source: Shanghai Henlius Biotech
• Contact: Shun Lu, Dr.
• Phone: 021-22200000
• Email: shunlu[@]sjtu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients with BRAF V600 mutation.

Description:

This is an open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients with BRAF V600 mutation. For the phase Ib study, HLX208 is administered orally at two dose levels of 600mg BID or 900 mg BID. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks. For the phase II study, HLX208 is administered orally with the RP2D dose. And HLX10 is administered intravenously at a fixed dose of 300mg every 3 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 49
• Est. completion date: February 27, 2026
• Est. primary completion date: March 4, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. =18 and =75 years old of age (in phase Ib study) or =18 and =80 years old of ag (in phase II study) at the time of informed consent.

2. Signed written informed consent.

3. BRAF V600E mutant advanced solid tumors (in phase Ib study) or advanced NSCLC (in phase II study) patients with positive PD-L1 expression (TPS or TC=1%).

4. Previous failure of standard therapy, intolerance to standard therapy, lack of standard therapy, or currently unsuitable for standard therapy.

5. Prior systemic anti-neoplastic therapy (chemotherapy, radiotherapy, targeted therapy, or traditional Chinese medicine with anti-neoplastic indications) must have been = 2 weeks from the first dose in this study with treatment-related AE resolved to NCI-CTCAE Grade = 1 (except for alopecia)

6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

7. Expected survival time = 3 months.

8. At least one measurable target lesion per RECIST v1.1 (brain metastasis could not be considered as the only measurable lesion).

9. With normal major organ functions (no blood transfusions or treatment with colony-stimulating factor within 14 days prior to the first dose in this study).

10. Be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bow

11. Fertile subjects (male or female) must agree to take effective contraceptive measures from the time of signing the ICF until 90 days after the last dose of HLX208 or 6 months after the last dose of HLX10. Female subjects of childbearing potential must complete a pregnancy test with a negative result within 7 days prior to the first dose.

Exclusion Criteria:

1. For subjects in phase II study: previous treatment with BRAF inhibitors or MEK inhibitors or previous treatment with T cell co-stimulation or immune checkpoint therapy.

2. Known EGFR mutations or ALK rearrangements (except in subjects with EGFR mutations whose disease has progressed after previous EGFR inhibitor treatment).

3. Received strong CYP3A inhibitors or inducers treatment within 1 week prior to the first dose of investigational product.

4. Received major surgery within 28 days prior to the first dose of investigational product. A major surgery is defined as a surgery that takes at least 3 weeks of postoperative recovery before receiving treatment in this study.

5. With uncontrolled pleural effusion, pericardial effusion, or ascites.

6. With symptomatic brain or meningeal metastases (unless the patient has been treated for >3 months, there is no evidence of progression on imaging within 4 weeks prior to the first dose, and the tumor-related clinical symptoms are stable).

7. With active pulmonary tuberculosis. Patients with previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity.

8. With any serious infection requiring systemic anti-infective therapy within 14 days prior to the first dose of the investigational product.

9. History of other malignant tumors (except for cured carcinoma in situ of the cervical or basal cell carcinoma of the skin) within two years prior to the first dose of investigational product.

10. Being positive (+) for hepatitis B surface antigen (HBsAg) or positive (+) for hepatitis B core antibody (HBcAb), and with hepatitis B virus deoxyribonucleic acid (HBV-DNA) = 2500 copies/mL or 500 IU/mL.

11. Being positive (+) for HCV RNA.

12. Being positive (+) human immunodeficiency virus (HIV) antibody.

13. History of serious cardiovascular and cerebrovascular diseases.

14. Systemic treatment with corticosteroids (> 10 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of the investigational product or during the study. In the absence of active autoimmune disease, subjects are allowed to use inhaled or topical steroids, or adrenal hormone replacement therapy at an effective dose equivalent to =10 mg/day prednisone.

15. Known active or suspected autoimmune diseases. Subjects with autoimmune related hypothyroidism receiving thyroid hormone replacement therapy are allowed to participate in the study. Subjects with stable type 1 diabetes receiving insulin therapy are allowed to participate in the study.

16. Known alcohol of or drug abuse.

17. Pregnant or lactating women.

18. Received live vaccine within 28 days prior to the first dose of investigational product.

19. Have other conditions not suitable for inclusion as judged by the investigator.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non Small Cell Lung Cancer

Intervention

Combination Product:
• HLX208+HLX10
HLX208 is a BRAF V600E inhibitor ,and HLX10 is an anti-PD-1 monoclonal antibody.

Locations

Country	Name	City	State
China	Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Henlius Biotech

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Association of biomarkers with efficacy	Association of efficacy with biomarkers including PD-L1 expression, BRAF V600E mutation abundance, MSI status and TMB status.	approximately up to 48 months
Primary	MTD (for phase Ib study)	The maximum tolerated dose of HLX208 combined with HLX10.	From first dose to the end of Cycle 1 (each cycle is 3 weeks).
Primary	DLT (for phase Ib study)	The proportion of patients experiencing dose limiting toxicity (DLT) events.	From first dose to the end of Cycle 1 (each cycle is 3 weeks).
Primary	ORR (for phase II study)	Objective response rate assessed by the investigator per RECIST 1.1.	up to approximately up to 24 months
Secondary	PFS	Progression-Free-Survival	approximately up to 36 months
Secondary	DCR	Disease-Control-Rate	approximately up to 24 months
Secondary	DOR	Duration of Overall Response	approximately up to 24 months
Secondary	TTR	Time to Tumor Response	approximately up to 24 months
Secondary	12-month OS rate	12-month OS rate	12 months
Secondary	6-month OS rate	6-month OS rate	6 months
Secondary	OS	Overall-Survival	approximately up to 48 months
Secondary	12-month PFS rate	12-month PFS rate	12 months
Secondary	6-month PFS rate	6-month PFS rate	6 months
Secondary	SAE	The proportion of patients experiencing SAE.	approximately up to 48 months
Secondary	AUC0-T	Area under the concentration-time curve from time 0 to the last concentration measurable time point.	From First administration of HLX 208 to 12 weeks.
Secondary	AUC0-8	Area under the concentration-time curve from time 0 to infinity.	From First administration of HLX 208 to 12 weeks.
Secondary	Cmax	Peak Plasma Concentration.	From First administration of HLX 208 to 12 weeks.
Secondary	Tmax	Time to first occurrence of Cmax	From First administration of HLX 208 to 12 weeks.
Secondary	t1/2	Elimination half-life	From First administration of HLX 208 to 12 weeks.
Secondary	AUCss	Area under the steady-state concentration-time curve	From First administration of HLX 208 to 12 weeks.